Search Result

Results for "

5-Aminosalicylic Acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Autophagy (1) Drug Intermediate (1) Drug Metabolite (2) Endogenous Metabolite (7) GCGR (3) GLP Receptor (2) Isotope-Labeled Compounds (7) NF-κB (9) PAK (9) PPAR (9)
By Research Areas:	Cancer (7) Inflammation/Immunology (12) Metabolic Disease (4) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Amino acid Transporter Amino Acid Derivatives Amino Acid Decarboxylase Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15027

5-Aminosalicylic Acid 15+ Cited Publications Mesalamine; 5-ASA; Mesalazine	PPAR PAK NF-κB Endogenous Metabolite	Inflammation/Immunology Cancer
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride Mesalamine-d₃ hydrochloride; 5-ASA-d₃ hydrochloride; Mesalazine-d₃ hydrochloride	Isotope-Labeled Compounds PPAR PAK NF-κB Endogenous Metabolite	Inflammation/Immunology Cancer
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-15027S1

5-Aminosalicylic acid-d3 Mesalamine-d₃; 5-ASA-d₃; Mesalazine-d₃	Isotope-Labeled Compounds Endogenous Metabolite NF-κB PAK PPAR	Inflammation/Immunology Cancer
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride Mesalamine-¹³C₆ hydrochloride; 5-ASA-¹³C₆ hydrochloride; Mesalazine-¹³C₆ hydrochloride	PPAR NF-κB PAK	Metabolic Disease
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-66008

N-Acetyl mesalazine N-Acetyl-5-Aminosalicylic Acid; N-Acetyl-ASA	Drug Metabolite	Inflammation/Immunology
N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the metabolite of 5-Aminosalicylic Acid (HY-15027) with endoscopic activity. N-Acetyl mesalazine can be used for the research of ulcerative colitis .

HY-15027R

5-Aminosalicylic Acid (Standard)	PPAR PAK NF-κB Endogenous Metabolite	Inflammation/Immunology Cancer
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-15027S4

5-Aminosalicylic acid-d7 5-ASA-d₇; Mesalamie-d₇; Mesalazie-d₇	Isotope-Labeled Compounds PPAR PAK Endogenous Metabolite NF-κB	Inflammation/Immunology Cancer
5-Aminosalicylic acid-d₇ (5-ASA-d₇; Mesalamie-d₇; Mesalazie-d₇) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .

HY-15027S3

5-Aminosalicylic acid-d3 disodium Mesalamine-d₃ disodium; 5-ASA-d₃ disodium; Mesalazine-d₃ disodium	PPAR NF-κB Endogenous Metabolite PAK Isotope-Labeled Compounds	Inflammation/Immunology
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and *NF-κB*.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-15027S2

5-Aminosalicylic acid-13C6 Mesalamine-¹³C₆; 5-ASA-¹³C₆; Mesalazine-¹³C₆	PPAR PAK NF-κB Endogenous Metabolite	Inflammation/Immunology
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].

HY-66008S2

N-Acetyl mesalazine-13C6 N-Acetyl-5-Aminosalicylic Acid-¹³C₆; N-Acetyl-ASA-¹³C₆	Isotope-Labeled Compounds Drug Metabolite	Inflammation/Immunology
N-Acetyl mesalazine-13C6 is a deuterated labeled N-Acetyl mesalazine . N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the metabolite of 5-Aminosalicylic Acid (HY-15027) with endoscopic activity. N-Acetyl mesalazine can be used for the research of ulcerative colitis .

HY-W206016

3-Aminosalicylic acid	Drug Intermediate	Inflammation/Immunology Cancer
3-Aminosalicylic acid is the impurity found during the 5-Aminosalicylic acid (HY-15027) production. 5-Aminosalicylic acid is the agonist for PPARγ and the inhibitor for p21-activated kinase 1 (PAK1) and NF-κB . Crohn's disease, ulcerative proctitis

HY-101744

Ipsalazide	Autophagy	Inflammation/Immunology
Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.

HY-131265

Mesalamine impurity P	PPAR PAK NF-κB	Inflammation/Immunology Cancer
Mesalamine impurity P is an impurity of Mesalamine (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-66008S

N-Acetyl mesalazine-d3 N-Acetyl-5-Aminosalicylic Acid-d₃; N-Acetyl-ASA-d₃	Isotope-Labeled Compounds	Others
N-Acetyl mesalazine-d₃ is the deuterium labeled N-Acetyl mesalazine[1].

HY-66008S1

N-Acetyl mesalazine-d3-1 N-Acetyl-5-Aminosalicylic Acid-d₃-1; N-Acetyl-ASA-d₃-1	Isotope-Labeled Compounds	Others
N-Acetyl mesalazine-d₃-1 is deuterium labeled 5-acetamido-2-hydroxybenzoic acid.

Cat. No.	Product Name	Target	Research Area

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15027

5-Aminosalicylic Acid 15+ Cited Publications Mesalamine; 5-ASA; Mesalazine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-15027R

5-Aminosalicylic Acid (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

Cat. No.	Product Name	Chemical Structure

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-66008S

N-Acetyl mesalazine-d3
N-Acetyl mesalazine-d₃ is the deuterium labeled N-Acetyl mesalazine[1].

HY-15027S4

5-Aminosalicylic acid-d7
5-Aminosalicylic acid-d₇ (5-ASA-d₇; Mesalamie-d₇; Mesalazie-d₇) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .

HY-15027S3

5-Aminosalicylic acid-d3 disodium
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and *NF-κB*.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].

HY-66008S2

N-Acetyl mesalazine-13C6
N-Acetyl mesalazine-13C6 is a deuterated labeled N-Acetyl mesalazine . N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the metabolite of 5-Aminosalicylic Acid (HY-15027) with endoscopic activity. N-Acetyl mesalazine can be used for the research of ulcerative colitis .

HY-66008S1

N-Acetyl mesalazine-d3-1
N-Acetyl mesalazine-d₃-1 is deuterium labeled 5-acetamido-2-hydroxybenzoic acid.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

5-Aminosalicylic Acid

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products